Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000036.xml
Download PDF
Laryngorhinootologie 2024; 103(06): 445-449
DOI: 10.1055/a-2109-6646
DOI: 10.1055/a-2109-6646
Der interessante Fall
Immunhistochemisches und molekulargenetisches Profil von Mantelzellymphomen der Glandula lacrimalis: eine detaillierte Beschreibung einer seltenen Tumorentität der Tränendrüse
Immunohistochemical and molecular genetic profile of mantle cell lymphoma of the lacrimal gland: a case series of an uncommon tumour of the lacrimal glandAuthors
Schlüsselwörter
Mantelzellymphom - Glandula lacrimalis - Immunphänotyp - Non-Hodgkin-Lymphom - BiopsiePublication History
Received: 30 January 2022
Accepted after revision: 03 November 2022
Article published online:
19 September 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Ferry JA, Fung CY, Zukerberg L. et al. Lymphoma of the ocular adnexa: A study of 353 cases. Am J Surg Pathol 2007; 31: 170-184
- 2 Knudsen MKH, Rasmussen PK, Coupland SE. et al. Clinicopathological Features of Ocular Adnexal Mantle-Cell Lymphoma in an International Multicenter Cohort. JAMA Ophthalmol 2017; 135: 1367-1374
- 3 Looi A, Gascoyne RD, Chhanabhai M. et al. Mantle cell lymphoma in the ocular adnexal region. Ophthalmology 2005; 112: 114-119
- 4 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Diagnostik, Therapie und Nachsorge für Patienten mit einem follikulären Lymphom, Langversion 1.0, 2020, AWMF-Registernummer: 018/033OL. Accessed November 05, 2022 at: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Follikulaeres_Lymphom/LL_Foll_Lymphom_Langversion_1.0.pdf
- 5 Wang ML, Rule S, Martin P. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507-516
- 6 Kluin-Nelemans HC, Hoster E, Hermine O. et al. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol 2020; 38: 248-256
- 7 Rule S, Dreyling M, Goy A. et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol 2017; 179: 430-438
- 8 Wang M, Rule S, Zinzani PL. et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 2018; 391: 659-667
- 9 Tam CS, Anderson MA, Pott C. et al. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. N Engl J Med 2018; 378: 1211-1223
- 10 Wang M, Munoz J, Goy A. et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 2020; 382 (14) 1331-1342
- 11 Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol 2019; 94: 710-725
- 12 Miao Y, Lin P, Saksena A. et al. CD5-negative Mantle Cell Lymphoma: Clinicopathologic Correlations and Outcome in 58 Patients. Am J Surg Pathol 2019; 43: 1052-1060
- 13 Hoster E, Rosenwald A, Berger F. et al. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. J Clin Oncol 2016; 34: 1386-1394
- 14 Kluin-Nelemans HC, Hoster E, Hermine O. et al. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol 2020; 38: 248-256